Core Viewpoint - A lawsuit has been filed against Fortrea Holdings Inc. and its senior executives for potential violations of federal securities laws, stemming from allegations of overstating cost savings and revenue projections related to transition services agreements following its spin-off from Labcorp [1][2][4]. Group 1: Company Background - Fortrea Holdings Inc. is a global contract research organization that provides biopharmaceutical product and medical device development solutions. It was spun off into a standalone, publicly traded company by Labcorp Holdings Inc. in June 2023 [3]. Group 2: Allegations and Lawsuit Details - The lawsuit claims that Fortrea overstated the cost savings and margin improvements expected from exiting transition services agreements with Labcorp, as well as the revenue from pre-spin projects [4]. - The case is pending in the U.S. District Court for the Southern District of New York, titled Deslande v. Fortrea Holdings Inc., et al., No. 1:25-cv-04630 [2]. Group 3: Stock Performance and Market Reaction - Following a report from Jefferies on September 25, 2024, which indicated that Fortrea's anticipated cost savings were not as significant as previously thought, the stock price fell by $2.73, or over 12%, from $22.21 to $19.48 per share [5]. - On March 3, 2025, Fortrea announced disappointing Q4 and full year 2024 financial results, leading to a further decline in stock price by $3.47, or over 25%, from $13.85 to $10.38 per share [6].

NEW YORK, June 6, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Fortrea Holdings Inc. ("Fortrea Holdings Inc." or the "Company") (NASDAQ: FTRE) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fortrea Holdings Inc. investors who were adversely affected by alleged securities fraud between July 3, 2023 and February 28, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/fo ...

NEW YORK, June 5, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers of Fortrea Holdings, Inc. (NASDAQ: FTRE) securities between July 3, 2023 and February 28, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 1, 2025.So what: If you purchased Fortrea securities during the Class ...

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Fortrea Holdings, Inc. (“Fortrea” or “the Company”) (NASDAQ: FTRE) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Fortrea ...

Core Viewpoint - A class action lawsuit has been filed against Fortrea Holdings Inc. for allegedly misleading investors regarding its financial performance and business prospects following its spin-off from Labcorp Holdings Inc. [1][5] Group 1: Company Background - Fortrea Holdings Inc. was spun off from Labcorp Holdings Inc. in June 2023, becoming a standalone publicly traded company [3] - Following the spin-off, Fortrea entered into transition services agreements with Labcorp for various support services [3] Group 2: Financial Performance - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA expectations for 2025 were not aligned with prior forecasts, leading to a significant stock price drop of $3.47 per share, or 25.05%, closing at $10.38 [4] - The company indicated that its Pre-Spin projects were underperforming and that post-spin work was not progressing quickly enough to compensate for the older projects' economic impact [4] Group 3: Allegations in the Lawsuit - The lawsuit claims that Fortrea overestimated revenue contributions from Pre-Spin projects and overstated potential cost savings from exiting transition services agreements [5] - It is alleged that the company's previously announced EBITDA targets for 2025 were inflated, misrepresenting the viability of its post-spin business model and financial prospects [5]

Core Viewpoint - Fortrea Holdings Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding its financial performance and business model following its spin-off from Labcorp Holdings Inc. [1][3] Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Deslande v. Fortrea Holdings Inc., and it includes purchasers of Fortrea securities from July 3, 2023, to February 28, 2025, with a deadline of August 1, 2025, to seek lead plaintiff status [1][2] - The lawsuit alleges that Fortrea overestimated revenue contributions from ongoing projects and overstated cost savings from exiting transition services agreements (TSAs), leading to inflated EBITDA targets for 2025 [3][4] Group 2: Financial Performance and Analyst Reports - On September 25, 2024, Jefferies downgraded Fortrea from buy to hold, citing weaknesses in its business model and stating that expected cost savings from exiting TSAs were not as significant as anticipated, resulting in a stock price drop of over 12% [4] - Following the cancellation of two scheduled conferences, Baird Equity Research downgraded Fortrea to neutral from outperform on December 6, 2024, leading to an additional stock price decline of more than 8% [5] - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA projections for 2025 were not aligned with prior expectations, revealing that pre-spin projects were underperforming, which caused the stock price to fall over 25% [6] Group 3: Company Background - Fortrea is a global clinical research organization (CRO) that provides development solutions for biopharmaceutical products and medical devices, having been spun off from Labcorp in June 2023 [2][3]

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Fortrea Holdings Inc. for alleged misrepresentations regarding the Company's EBITDA targets for 2025, affecting investors who acquired securities between July 3, 2023, and February 28, 2025 [1][2]. Group 1 - The lawsuit is on behalf of investors who purchased or acquired Fortrea's securities during the specified period [1]. - Defendants are accused of making misrepresentations concerning the Company's financial targets, specifically the EBITDA targets for 2025 [2]. - Investors wishing to serve as lead plaintiff must file papers by August 1, 2025, and can remain absent class members if they choose not to take action [3]. Group 2 - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has represented both individual investors and large pension funds [4]. - The firm has been recognized for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [4].

Core Points - A shareholder class action lawsuit has been filed against Fortrea Holdings, Inc. alleging that the company made materially false and misleading statements regarding its business and financial prospects [1] - The lawsuit claims that Fortrea overestimated revenue contributions from Pre-Spin Projects and overstated cost savings from exiting transition services agreements [1] - As a result of these allegations, Fortrea's previously announced EBITDA targets for 2025 are said to be inflated, raising concerns about the viability of its post-Spin-Off business model [1] Legal Context - Shareholders who purchased Fortrea shares between July 3, 2023, and February 28, 2025, and suffered significant losses are encouraged to discuss their legal rights [2] - The deadline for shareholders to request to be appointed as lead plaintiff in the case is August 1, 2025 [3] - Holzer & Holzer, LLC is representing shareholders in this litigation and has a history of recovering significant amounts for investors affected by corporate misconduct [3]

Core Viewpoint - A securities class action lawsuit has been filed against Fortrea Holdings, Inc. for allegedly making false and misleading statements regarding its financial performance and business prospects during the class period from July 3, 2023, to February 28, 2025 [1]. Group 1: Allegations - The complaint claims that Fortrea overestimated the revenue contributions from its Pre-Spin Projects for 2025 earnings [2]. - It is alleged that Fortrea overstated the cost savings expected from exiting the TSAs [2]. - The company's previously announced EBITDA targets for 2025 were reportedly inflated due to these misrepresentations [2]. - The viability of Fortrea's post-Spin-Off business model and its financial prospects were also claimed to be overstated [2]. - Consequently, the public statements made by Fortrea were materially false and misleading throughout the relevant period [2]. Group 2: Investor Information - Investors who purchased shares of Fortrea are encouraged to contact the law firm before the lead plaintiff motion deadline on August 1, 2025 [3]. - A lead plaintiff will act on behalf of other class members in directing the litigation [3].

Core Viewpoint - A class action lawsuit has been filed against Fortrea Holdings, Inc. for allegedly misleading investors regarding the progress and financial expectations of its Pre-Spin projects [1][2][4]. Company Overview - Fortrea Holdings, Inc. is a global contract research organization (CRO) that provides development solutions for biopharmaceutical products and medical devices [1]. - The company was spun off from Labcorp Holdings Inc. in June 2023 and operates as a standalone publicly traded entity [2]. Financial Performance - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA projections for 2025 were not meeting prior expectations, indicating that its Pre-Spin projects were underperforming [3]. - The company reported that its Pre-Spin projects were "late in their life cycle" and had lower revenue and profitability than anticipated for 2025 [3]. - Fortrea's stock price dropped by $3.47 per share, or 25.05%, closing at $10.38 per share following the announcement of disappointing financial results [3]. Allegations and Misstatements - The lawsuit claims that Fortrea overestimated the revenue contributions from its Pre-Spin projects and overstated potential cost savings from exiting transition services agreements (TSAs) [4]. - It is alleged that the company's previously announced EBITDA targets for 2025 were inflated, leading to an overstatement of its post-Spin-Off business model viability and financial prospects [4].